Griseofulvin is FDA approved for and the drug of choice in tinea capitis. Other indications include onychomycosis as well as superficial fungal infections resistant to topical antifungal medications. This activity will highlight the mechanism of action, adverse event profile, monitoring, and relevant interactions of griseofulvin, pertinent for members of the interprofessional team in the treatment of patients with the conditions mentioned above when using griseofulvin.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/22435
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - MOC Credit Details: ABS - 1.5 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.5 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.5 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.5 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Chemical Pathology, Dermatopathology, General Pediatrics, General Surgery, Infectious Disease, Infectious Diseases/Medical Microbiology, Internal Medicine, Pediatric Infectious Diseases
Subscribe
Login
0 Comments
Oldest